Hepatitis C virus (HCV) is an enveloped RNA virus belonging to the Flaviviridae family. Each year, HCV infects approximately three-four million individuals worldwide. It is estimated that 170 million people are chronically infected with HCV and at risk of developing chronic liver disease and 350,000 deaths occur each year due to HCV-related causes ([@B9]). HCV is present worldwide, but its distribution pattern is not uniform. In Latin America, HCV genotype 1 is the most prevalent and the overall prevalence of HCV antibody is estimated to be 1.5% ([@B1]). In Mexico, an identified region with low HCV prevalence, the most prevalent viral genotypes are 1a and 1b followed by 2a and 3b ([@B13]. In recent years, chronic diseases associated with liver malfunction have gained increasing importance in the world ([@B6]; thus, the study of causal agents of liver damage is of great significance.

HCV is able to establish lifelong persistent infection in most individuals by successfully evading the immune system. However, approximately 30% of patients spontaneously clear the virus ([@B15]). The immunopathology associated with HCV infection has been predominantly studied in regions where infection is common and the results have been extrapolated to regions of low endemicity. The exact mechanisms responsible for viral clearance and recovery in humans are unknown. In this context, efforts to determine whether biomarkers, including serum cytokines, can accurately predict the outcome of HCV infection are valuable for establishing better HCV control strategies in Latin American regions.

In the present study, 33 serum samples from patients (\> 18 years of age) admitted to the Molecular Biology Service of the Fray Antonio Alcalde Civil Hospital of Guadalajara (AHCFAA) from 2011-2013 were retrospectively analysed. Hepatitis was defined as described in a previously published study ([@B4]. Informed consent was obtained from all patients involved in the study. The local ethical committee of the AHCFAA approved the study protocol.

Samples from patients with liver disease and under treatment with a hepatotoxic drug, patients with chronic hepatitis associated with an aetiological agent distinct to viral hepatitis, patients with autoimmune hepatitis and patients identified as overweight or obese were excluded from the study. Clinical history and demographic data were collected for all participants through a structured questionnaire, as previously reported ([@B4]). Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured using an enzymatic method (Human, Germany) with an automatic analyser. The abnormal cut-off values for ALT and AST enzymes were 40 UI/mL and 50 UI/mL, respectively.

*Clinical evaluation of HCV-infected patients* - Chronic HCV infection was defined as a positive anti-HCV test (ELISA Third-Generation, AxSYM) result and the presence of serum HCV RNA for more than six months (COBAS^®^AmpliPrep and COBAS^®^TaqMan 48). Samples from patients who spontaneously cleared HCV tested positive for anti-HCV antibody in the absence of HCV RNA six months after the initial test, in accordance with the definition of spontaneous viral clearing ([@B9], [@B3]). AST and ALT levels were determined by dry chemistry on a Vitros 250 analyser (Ortho Clinical Diagnostics, Johnson & Johnson, USA). Viral genotyping was performed at the Bayesian Markov model through a conventional line probe assay (VERSANT HCV Genotype 2.0 Assay LiPA, Germany) after HCV RNA extraction (QIAamp RNA mini kit) and RNA amplification (VERSANT HCV LiPA 2.0 Amplification Kit) following the manufacturer's instructions.

Patients with positive viral RNA were stratified into four groups according to their fibrosis stage, as determined by transitional elastography using a FibroScan^®^instrument (Echosens, France). As validated by the manufacturer, the stage of fibrosis in patients with chronic HCV infection was defined as follows: F1, initial fibrosis, F2, moderate fibrosis, F3, advanced fibrosis, and F4, cirrhosis stage.

*Analysis of serum cytokines* - As reported previously, a standardised ([@B7]) dot blot-based assay was used according to the manufacturer's instructions (Ray-Biotech, USA) to detect the relative expression levels of 23 cytokines in serum samples collected from patients. The following cytokines were analysed: pro-inflammatory cytokines \[interleukin (IL)-8, tumour necrosis factor-alpha (TNF-α), IL-2, IL-1 and IL-6\], anti-inflammatory cytokines \[tumour growth factor-beta (TGF-β) and IL-10\], fibrogenic (IL-13), immunoregulatory cytokines \[IL-5, IL-15, interferon-gamma (IFN-γ), IL-7 and TNF-β\], chemokines \[monocyte chemoattractant protein (MCP)-1 (CCL-2), MCP-2 (CCL-8), MCP-3 (CCL-7), monokine-induced by IFN-γ (MIG) (CXCL-9) and regulated upon activation, normal T-cell expressed and secreted (RANTES) (CCL-5)\] and growth factors \[growth-regulated oncogene-alpha (GRO-α), GRO, IL-3, granulocyte-macrophage colony-stimulating factor (GMCSF) and granulocyte colony-stimulating factor (GCSF)\] ([@B7]). Briefly, the membranes were blocked with a blocking buffer and 1 mL of a 1:500 dilution of the patient serum was added. Next, the membranes were incubated at room temperature (RT) for 2 h. After the membranes were washed, 1 mL of primary biotin-conjugated antibodies was added to detect the 23 cytokines previously described and the membranes were incubated at RT for 2 h. The membranes were incubated with 2 mL of horseradish peroxidase-conjugated streptavidin at RT for 1 h, which was developed using an enhanced chemiluminescence-type solution subsequently exposed to film and processed by autoradiography. The densitometry analysis was performed with an Alpha-Innotech FluorChem Imaging System. For each membrane, the individual background value obtained from the densitometry values for the blank controls included in each assay (A in [Figure](#f01){ref-type="fig"}) were subtracted from the densitometry values corresponding to each cytokine. The densitometry units corresponding to the relative expression levels of each cytokine are shown.

The cytokine profiles during hepatitis C virus (HCV) infection distinguish viral clearance from persistent infection. Representative dot blots of the study groups are shown (A: chronically HCV-infected patients with detectable viral RNA titres; B: patients who spontaneously cleared HCV; C: an array map). The dot blot assay was used according to the manufacturers' instructions to detect the cytokine levels in serum samples collected from patients (Ray-Biotech). For each membrane, the individual background levels were subtracted. Individual densitometry analyses and averages for each group are shown \[D: interleukin-1 alpha (IL-1α); E: tumour necrosis factor-alpha (TNF-α); F: tumour growth factor-beta (TGF-β); G: IL-10; H: IL-8; I: monocyte chemoattractant protein (MCP)-2; J: regulated upon activation, normal T-cell expressed and secreted (RANTES); K: IL-13; L: IL-15\]. Chronically HCV-infected patients were defined as patients with positive anti-HCV test results and detectable HCV genotype 1a viral RNA titres (HCV+) and patients who spontaneously cleared HCV presented positive anti-HCV test results and undetectable HCV RNA titres (HCV-). Differences with p \< 0.05 were considered statistically significant (\*: p \< 0.05; \*\*: p \< 0.001). DU: densitometry units (refer to the relative expression levels of detected cytokines); IFN-γ: interferon-gamma; MIG: monokine-induced by IFN-γ; TNF-β: tumour necrosis factor-beta.

*Ethics* - Blood from patients and controls was obtained by venipuncture with approval from the local ethical committee of the HCFAA (IRB: HCG/CI-883/09). The protocol was conducted in accordance with the Helsinki Declaration of 1975, as revised in 1983.

*Statistical analysis* - The data are reported as individual densitometry analyses for each patient for each cytokine. The mean ± standard deviation (SD) for study groups is indicated. The data are presented as the mean ± SD. Statistical comparisons were performed using GraphPad Prism v.5.01. A nonparametric Mann-Whitney *U* test was used to calculate the statistical significance of the assay results. A p value ≤ 0.05 was considered statistically significant. Significant p values were corrected using the Bonferroni method to ensure that there were differences between the compared groups.

RESULTS
=======

Based on HCV antibody and RNA viral profiles, patients were stratified into two groups: patients who spontaneously cleared HCV and patients with chronic HCV infection who continued to have detectable RNA titres. There were no significant gender or age differences found between the analysed groups. However, the patients with chronic HCV infection and detectable viral RNA presented significantly increased ALT and AST levels compared with the patients who had spontaneously cleared HCV. Genotype 1a was found in all of the chronically infected patients with detectable RNA. Fibrosis staging determined by elastography was conducted in a small number of participants (6) from the chronic HCV group. Patients with distinct stages of liver disease were included in the study and cirrhosis (F4) was found exclusively in one of these patients ([Table](#t1){ref-type="table"}).

TABLEClinical and demographic characteristics of the patientsCharacteristicsHCV+ (n = 16)HCV- (n = 17)pGender \[female (%)\]68.7576.4-Mean age (years ± SD)53.13 ± 10.349.12 ± 12.830.332Mean ALT (UI/L ± SD)64.43 ± 41.1429.8 ± 15.070.005Mean AST (UI/L ± SD)61.86 ± 42.4529.8 ± 16.740.012Positive anti-HCV1617-Viral genotype1aUndetectable-Mean viral titre (UI/L ± SD)1.064 x 10\^7 ± 1.56 x 10\^7Undetectable-Lipid profile (mg/dL)    COL170.2 ± 52.67177.3 ± 59.420.724 TG157.3 ± 76.96148.6 ± 63.40.728 HDL38.27 ± 9.7440.29 ± 7.60.514 LDL100.5 ± 50.78119.9 ± 340.210 VLDL31.4 ± 15.2830.29 ± 130.826Body mass index (kg/m^2^)22.94 ± 1.3822.9 ± 1.260.925Grade of fibrosis (n)   F11\--F1-F21\--F21\--F2-F32\--F41\--[^1]

In an attempt to rule out the influence of overweight and obesity on the clearance or evolution of chronic HCV infection, this study only included samples from patients with a normal body mass index. No differences in the lipid profiles of the analysed groups were found ([Table](#t1){ref-type="table"}). Representative dot blots showing the relative expression of cytokines in the study groups are shown in A, B in [Figure](#f01){ref-type="fig"}. A low detection rate of certain cytokines, including IL-2, IL-6, IL-5, IFN-γ, IL-7, TNF-β, MCP-1 (CCL-2), MCP-3 (CCL-7), MIG (CCL-9), GRO-α, GRO, IL-3, GMCSF and GCSF, was observed in our study groups (A-C in [Figure](#f01){ref-type="fig"}). Interestingly, compared with chronic HCV-infected patients with detectable RNA, the patients who spontaneously cleared HCV displayed increased levels of IL-1α, TNF-α, TGF-β, MCP-2 (CCL-8), IL-13 and IL-15 (D-F, I, K, L in [Figure](#f01){ref-type="fig"}, respectively). In contrast, the chronic HCV-infected patients with detectable RNA showed increased levels of IL-8 and RANTES (CCL-5) compared with patients who spontaneously cleared HCV (H, J in [Figure](#f01){ref-type="fig"}, respectively). No significant differences were found in IL-10 levels. However, there was a trend towards increased IL-10 levels in the chronic HCV-infected patients with detectable RNA (G in [Figure](#f01){ref-type="fig"}).

Viral and host factors are related to the progression of HCV infection. In 2009, it was demonstrated that HCV viral clearance is associated with genetic variation in the *IL-28B* gene ([@B8], [@B17], [@B14]). Numerous studies have been conducted on this family of cytokines and have led to several inconsistencies and controversies, including the possible correlation between serum protein levels and disease outcomes in chronic viral hepatitis patients ([@B18]). Thus, it is accepted that variations in the profile of cytokines involved in the immune response may contribute to the ability to clear HCV. These studies have mainly been conducted in regions where the virus is endemic ([@B16]), thus information on populations in regions of low endemicity is scarce. Herein, we characterised serum cytokine expression profiles in Mexican HCV-infected patients and found subtle differences in the cytokine profiles between distinct clinical courses of HCV infection. In our study, persistent infection with detectable genotype 1a viral content resulted in a proinflammatory profile characterised by increased levels of IL-8 and RANTES (CCL-5) and a trend towards increased IL-10 levels. These findings correlate with in vitro studies that have shown that natural killer cells from HCV-infected patients are impaired in their capacity to activate dendritic cells due to the overproduction of IL-10 ([@B11]). Likewise, the increased levels of IL-8 found in the chronic HCV group in the present study may be related to the association between IL-8 production and IFN-α inhibition described in both in vivo and in vitro studies ([@B12], [@B10])*.* Moreover, the analysis of cytokines in each patient revealed a trend towards higher serum concentrations of IL-10 and IL-8 in patients with more severe liver damage (F2-F3 and F4) (data not shown). Altogether, our findings suggest that IL-10 and IL-8 overproduction may contribute to a lower probability of viral clearance, whereas homeostasis between pro-inflammatory \[IL-1 α, TNF-α, MCP-2 (CCL-8)\], anti-inflammatory (TGF-β), fibrogenic (IL-13) and immunoregulatory (IL-15) profiles allows for viral clearance, as observed in patients with undetectable viral RNA levels. However, large-scale studies with adequate statistical power to support this hypothesis are needed. Furthermore, given that our data do not rule out the possibility that cytokine levels may be a consequence and not the cause of HCV clearance, future studies aimed at analysing the possibility of a reverse causation are necessary.

The progression of HCV infection is associated with the characteristics of lipid profiles in chronic HCV patients. In fact, it is accepted that lipid components associated with HCV infection are finely modulated in the Mexican population ([@B6]). In the present study, no association between lipid profiles and viral clearance was found. Future studies that include overweight and obese individuals will allow the determination of the exact role of lipids in viral clearance.

We previously reported the influence of cytokines on the development of distinct clinical courses in children infected with hepatitis A ([@B5], [@B2]) and on the development of occult hepatitis B virus infection in native Mexican groups ([@B7]). Herein, our findings suggest that cytokine expression can influence the extent of HCV development and provide important insights into cytokine-mediated mechanisms underlying the long-term persistence of HCV. In this context, efforts to determine whether biomarkers, including serum cytokines, can accurately predict the outcome of HCV infection are valuable for establishing better HCV control strategies in Latin American regions.
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[^1]: ALT: alanine aminotransferase; AST: aspartate aminotransferase; COL: cholesterol; HCV-: patients who exhibited positive anti-hepatitis C virus test results and undetectable HCV RNA titres for more than six months. Averages of quantitative variables are expressed as mean ± standard deviation (SD); HCV+: chronically HCV-infected patients who exhibited positive anti-HCV test results and detectable HCV genotype 1a viral RNA titres for more than six months; HDL: high density lipoprotein; LDL: low density lipoprotein; TG: triglyceride; VLDL: very low density lipoprotein.
